Harmony Biosciences Holdings, Inc. (HRMY) Form 8-K — Nov 4, 2026
Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9 million, up 12% year over year, driven by 400 net patient adds and reiterating full-year guidance of $1.0B to $1.04B. Net income fell 5% to $48.2 million ($0.81 diluted EPS vs $0.87), weighed down by a $25 million MSN license milestone charge and new Novitium royalties that pushed cost of product sold from 25% to 30% of revenue. Cash and investments grew $89 million in the quarter to $1.05 billion. The company disclosed favorable preliminary multiple-ascending dose data for its orexin agonist BP-205, with no serious adverse events, keeping Phase 1b data on track for Q1 2027 and Phase 2 starts by mid-2027.
Key figures
- Eps
- 0.81
- Revenue
- 268917000
- Guidance
- Full-year 2026 WAKIX net revenue of $1.0B to $1.04B reiterated
- Net Income
- 48196000
- Revenue Yoy
- 12%
- Total Assets
- 1478245000
- Cash Position
- 1051600000
- Shares Outstanding
- 58720081
- Rd expense
- 71663000
- Q3 2025 revenue
- 239455000
- Average patients
- 9350
- Net patient adds
- 400
- Nine month revenue
- 745584000
- Q3 2025 net income
- 50865000
- Q3 2025 diluted eps
- 0.87
- Cost of product sold
- 80686000
- Nine month net income
- 156115000
- Msn license milestone charge
- 25000000
- Clinical milestone zyn002 prior year
- 15000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.